13.92USD-1.90%Mkt Cap: 1.97B USDP/E: —Last update: 2026-06-01
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IP…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.97B USD
Enterprise Value1.84B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-42.76M USD
Revenue/Share—
Last Price13.92 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees34
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-25.35
PEG—
EV/EBITDA-34.90
EV/Revenue—
P/S—
P/B10.55
EPS (TTM)-0.32
EPS (Forward)-0.56
52W Range
5.38080% of range16.12
52W High16.12 USD
52W Low5.380 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.33%
ROA-22.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-42.09M USD
CapEx (TTM)12.00K USD
FCF Margin—
FCF Yield-1.45%
Net Debt-171.10M USD
Net Debt/EBITDA3.25
Balance Sheet
Debt/Equity0.00
Current Ratio24.75
Quick Ratio24.30
Book Value/Sh1.340 USD
Cash/Share1.210 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)23.90 USD
Target Range20.00 USD – 30.00 USD
# Analysts10
Ownership
Shares Out.141.98M
Float117.83M
Insiders0.63%
Institutions98.21%
Short Interest
Short Ratio7.1d
Short % Float10.39%
Short % Out.9.36%
Shares Short13.29M
Short (prev mo.)16.14M
Technical
SMA 5013.52 (+2.9%)
SMA 20011.35 (+22.7%)
Beta1.08
S&P 52W Chg27.70%
Avg Vol (30d)1.43M
Avg Vol (10d)1.08M
Technical Indicators
RSI (14)51.3
MACD0.1389
MACD Signal0.1936
MACD Hist.-0.0547
BB Upper15.30 USD
BB Middle14.31 USD
BB Lower13.31 USD
BB Width13.92%
ATR (14)0.7101 USD
Vol Ratio (20d)0.32x